News

Best Life on MSN2h
Ozempic and Wegovy May Have Landed 25,000 People in the ER—Here's the Scary Reason Why
Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.
The top reasons Ozempic users are going to the hospital — and the ‘Wild West’ factor that could be driving an unexpected issue
Though popular weight loss jabs like Ozempic and Wegovy have been deemed safe and effective by the FDA, concerning side ...
Applied Clinical Trials Online23h
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...
Weight-Loss Drugs Have Sent a Shocking Number of People to the Emergency Room, New Study Claims
A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...
Healio1d
Semaglutide tied to significant improvements in MASH, liver fibrosis at 72 weeks
Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...
HealthDay on MSN20h
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...
Active ingredient in weight loss drug Wegovy may help treat type of fatty liver disease: Study
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.
US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
Not only for weight loss: This is the other condition Ozempic may help you with according to a new study
In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.